Drs. Clark and Rosenthal are paid members of the TriPath Oncology Scientific Advisory Board. The terms of this arrangement are managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx™ C)
Article first published online: 24 OCT 2006
Copyright © 2006 American Cancer Society
Volume 108, Issue 6, pages 494–500, 25 December 2006
How to Cite
Kelly, D., Kincaid, E., Fansler, Z., Rosenthal, D. L. and Clark, D. P. (2006), Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx™ C). Cancer, 108: 494–500. doi: 10.1002/cncr.22288
- Issue published online: 11 DEC 2006
- Article first published online: 24 OCT 2006
- Manuscript Revised: 8 AUG 2006
- Manuscript Accepted: 8 AUG 2006
- Manuscript Received: 21 JUN 2006
- TriPath Oncology, a division of TriPath Imaging Inc.
- cervical cytology;
- liquid-based cytology;
- high-grade squamous intraepithelial lesion
Routine liquid-based cytology (LBC) provides excellent sensitivity for the detection of cervical high-grade squamous intraepithelial lesion (HSIL); however, its specificity is low. Consequently, many women who have atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL) cytology undergo unnecessary colposcopy. The authors hypothesized that a novel immunocytochemical assay (ProEx™ C) that can be performed on LBC slides had a significantly higher positive predictive value (PPV) for biopsy-proven HSIL compared with routine LBC.
The ProEx™ C immunocytochemical assay utilizes a cocktail of monoclonal antibodies directed against proteins associated with aberrant S-phase cell cycle induction (topoisomerase IIA, minichromosome maintenance protein 2). The ProEx™ C reagents were validated in the authors' laboratory for staining and scoring reproducibility, open-vial stability, and accuracy before a retrospective analysis using these reagents was performed on 317 residual cytology samples. Sensitivity, specificity, PPV, and negative predictive value (NPV) for the detection of biopsy-proven HSIL were determined.
The ProEx™ C assay was validated successfully in the authors' cytology laboratory. Using biopsy-proven HSIL as an endpoint, the ProEx™ C assay yielded a sensitivity of 85.3%, specificity of 71.7%, PPV of 44.6%, and NPV of 94.8%. Compared with the routine LBC results in the same cohort, the ProEx™ C sensitivity for biopsy-proven HSIL was 70.6% greater than HSIL+ cytology (50% vs. 85.3%). ProEx™ C also showed a 114% increase in PPV relative to ASC-US cytology (21.1% vs. 44.6%).
The ProEx™ C immunocytochemical assay can be integrated into a clinical cytology laboratory and may increase the PPV of LBC for biopsy-proven HSIL. Cancer (Cancer Cytopathol) 2006. © 2006 American Cancer Society.